Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.26 -0.56 (-2.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Investors Search for Clues in Economic Data, Recession Signals ↗

July 06, 2022

Stocks are extending this morning's quiet losses, as investors continue to keep an eye on signs of an oncoming recession.

Via Talk Markets

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial ↗

July 06, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗

July 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Where Sarepta Therapeutics Stands With Analysts ↗

June 24, 2022

Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings within the last quarter:

Via Benzinga

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial ↗

June 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Expert Ratings for Sarepta Therapeutics ↗

May 19, 2022

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:

Via Benzinga

Sarepta Therapeutics: Q1 Earnings Insights ↗

May 04, 2022

Sarepta Therapeutics (NASDAQ:SRPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study ↗

June 23, 2022

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership ↗

February 01, 2022

Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to

Via Benzinga

Analyst Ratings For Sarepta Therapeutics ↗

January 18, 2022

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:

Via Benzinga

Expert Ratings For Sarepta Therapeutics ↗

December 09, 2021

Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed th...

Via Benzinga

Sarepta Therapeutics's Earnings: A Preview ↗

May 03, 2022

Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

7 Potential Biotech Stocks Buyout Targets in 2022 ↗

April 21, 2022

Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.

Via InvestorPlace

Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating ↗

April 07, 2022

On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier.

Via Investor's Business Daily

Tough Slogging Ahead for Investors, Diversification is Important ↗

March 07, 2022

Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.

Via Talk Markets

Where Sarepta Therapeutics Stands With Analysts ↗

March 02, 2022

Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and...

Via Benzinga

Sarepta Therapeutics: Q4 Earnings Insights ↗

March 01, 2022

Sarepta Therapeutics (NASDAQ:SRPT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

Sarepta Therapeutics's Earnings Outlook ↗

February 28, 2022

Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 14, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

Sarepta Abandons Lysogene-Partnered Pivotal-Stage Gene Therapy Candidate ↗

January 13, 2022

Sarepta Therapeutics Inc (NASDAQ: SRPT) is walking away from a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on...

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

January 05, 2022

UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021 ↗

November 05, 2021

Upgrades For IGM Biosciences Inc (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 ↗

December 09, 2021

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today